Eliminate and reduce packaging materials for existing products (no numeric target or year)
Latest reported: Not reported
From the source“Eliminate and reduce packaging materials as regulations allow and technology enables for existing products.”
Pharma and health
Pfizer is a pharmaceutical company. Its packaging page sets qualitative aims to cut packaging materials and run take-back programs, without numeric targets.
Formats and materials the company itself reports using, in its own reporting. No pack specifications, volumes or supplier names beyond what it has published.
| Format | Material | What the company reports |
|---|---|---|
| Tertiary shipment packaging | Mixed | 3R Circular Program prioritises reduction, reuse and recycling of high-volume tertiary shipment materials4 |
| Cold chain blankets, pallets | Thermal blankets, wood | Piloting reuse of cold chain thermal blankets and lighter-weight wooden pallets4 |
| All packaging | Not specified | Packaging aims: eliminate and reduce packaging materials for existing products as regulations allow; minimise and optimise packaging for new launches; select materials with lower GHG profiles, fewer chemicals of concern and more recycled material; take-back programs for packaging with suppliers5 |
| Design tool | Not specified | Internal life cycle assessment tool used by package designers5 |
Reporting scope: The 2025 Impact Report covers 1 January to 31 December 2025 unless otherwise noted. No packaging tonnage or packaging KPIs are reported in the sections read.4
No packaging supplier relationship is publicly announced in the sources reviewed. The packaging page refers to collaboration and take-back programs with suppliers without naming them.
Targets and progress are taken from each company's own published reports, with a quote and a link on its page. Status shows met or missed only where the company has reported the result. No contacts, purchase volumes, supplier relationships or pack specifications are listed.
Latest reported: Not reported
From the source“Eliminate and reduce packaging materials as regulations allow and technology enables for existing products.”
Latest reported: 72% (2025)
From the source“driving 64% of our suppliers of goods and services by spend to also set science-based GHG emission reduction goals by 2025”
Latest reported: Not reported for Scope 3 total; SBTi validation paused in 2024
From the source“By 2040, we aim to decrease our company's GHG emissions by 95% and our value chain emissions by 90% from 2019 levels”
Every packaging and supply-chain commitment the company has published, with its baseline and the latest progress it reports. Status says met or missed only where the company states the result.
| Commitment | By | Baseline | Latest reported | Status |
|---|---|---|---|---|
| Green Journey packaging aimsEliminate and reduce packaging materials for existing products as regulations allow and technology enables; minimise packaging for new launches; maximise recycled materials (no numeric target or year)5 | – | Not reported | In progress | |
| Net zero 204064% of purchased goods and services suppliers by spend to set science-based GHG reduction targets by 20258Purchased goods and services suppliers include packaging suppliers (SPI note) | 2025 | – | 72% of suppliers (2025) | Met |
| Net zero 2040Reduce value chain (Scope 3) emissions by 90% by 2040 vs 2019; Scope 1 and 2 down 46% by 2030 and 95% by 20406 | 2040 | 2019 | Scope 1 and 2 down 40.9% vs 2019; SBTi validation of the net-zero target paused in 2024 (2025) | In progress |
Pfizer's packaging commitments are qualitative. Its Green Journey packaging page sets four aims without numbers or dates: eliminate and reduce packaging on existing products as regulations allow and technology enables; minimise and optimise packaging for new launches; choose materials with lower greenhouse gas profiles, fewer chemicals of concern and more recycled material; and run take-back programmes for packaging with suppliers5. Package designers use an internal life cycle assessment tool to estimate the impact of designs5.
The numeric targets shown in the register on this page are climate targets. The goal that 64% of purchased goods and services suppliers by spend set science-based greenhouse gas targets by 2025 is a supplier-climate target, not a packaging target: it counts suppliers of every kind by spend and measures whether they have set emissions goals, not packaging material, weight or recyclability8. Packaging suppliers are among those counted, but meeting it shows nothing about Pfizer's packaging. The same holds for the 2040 net-zero goal, which includes a 90% cut in value chain emissions from 20196.
The packaging work disclosed in the 2025 Impact Report, published on 2 June 2026, is in distribution: the 3R Circular Program for high-volume tertiary shipment materials, with pilots of reusable cold chain thermal blankets and lighter wooden pallets4. Pfizer is a founding member of the Pharmaceutical Supply Chain Initiative4, an industry body for supplier standards rather than a packaging coalition.
SPI analysis Our reading of the sourced facts above. Not company-reported, not legal advice.
None of Pfizer's packaging aims has a target value, so there is no packaging progress to calculate, and the 2025 Impact Report gives no packaging tonnage, material split or packaging KPI4.
Supplier science-based targets: 72% of suppliers by spend in 2025 against the 64% goal8. SPI calculation: 8 points above the goal. The goal is met, but it is a climate engagement result and should not be read as packaging progress, because it measures suppliers' target-setting rather than any change in the cartons, shippers or pallets Pfizer uses.
Operational emissions: Scope 1 and 2 were 40.9% below 2019 in 2025, against 46% by 20306. SPI calculation: 5.1 points remain over five years, about 1 point a year. Scope 3 progress toward the 90% by 2040 goal is not stated in the report sections cited, and Pfizer paused SBTi validation of its net-zero target in 20246, so value chain pace, where purchased packaging sits, cannot be tested.
Tertiary packaging pilots: the report describes pilots, not quantities, so SPI cannot size the reusable blanket or pallet programmes.
Scale: total revenues were USD 62,579 million in 2025 against USD 63,627 million in 20242, with medicines and vaccines supplied to about 200 countries and territories from 36 manufacturing sites17. Packaging use follows volumes, but no volume measure is reported.
2025 Impact Report: 3R Circular Program focuses on reducing, reusing and recycling high-volume tertiary shipment materials, with pilots reusing cold chain thermal blankets and lighter-weight wooden pallets; 72% of suppliers by spend have science-based targets against a 64% goal.4
SPI analysis Our reading of the sourced facts above. Not company-reported, not legal advice.
Basis: Presence is taken from subsidiaries listed in Exhibit 213 and the 10-K statement that medicines and vaccines are supplied to about 200 countries and territories1. Pfizer sells prescription medicines and vaccines, so beverage deposit and food-contact PFAS rules do not apply. Many packaging laws give medicinal products partial exemptions (for example PPWR recyclability and recycled-content exemptions for medicinal immediate packaging, the UK Plastic Packaging Tax exemption for immediate packaging of licensed human medicines, and drug-packaging exemptions in several U.S. state EPR laws); these were not checked rule by rule. Rule IDs are from the SPI Regulation Tracker. Applicability is SPI's reading, not legal advice.
| Jurisdiction | Rules in the Regulation Tracker |
|---|---|
| European UnionSubsidiaries in many Member States, for example Pfizer Deutschland GmbH, Pfizer, S.L.U.3 |
Secondary and transport packaging (cartons, shippers) is in scope; immediate medicinal packaging has exemptions from some PPWR design and recycled-content rules. |
| GermanyPfizer Deutschland GmbH3 | |
| FrancePfizer Holding France3 |
Applicability of Triman labelling to medicines not checked. |
| SpainPfizer, S.L.U.3 |
Any exemption for medicinal packaging under the Spanish plastic tax not checked. |
| AustriaPfizer Manufacturing Austria G.m.b.H.3 | Tracker rule is beverage deposit only. |
| IrelandPfizer Healthcare Ireland Unlimited Company3 | Tracker rule is beverage DRS only. |
| PortugalLaboratórios Pfizer, Lda.3 | Tracker rule is beverage DRS only. |
| PolandPfizer Polska Sp. z.o.o.3 | Tracker rule is beverage DRS only. |
| United KingdomHospira UK Limited and other UK subsidiaries3 |
Immediate packaging of licensed human medicines is exempt from Plastic Packaging Tax; secondary and transport plastic is not. |
| United StatesHeadquarters1 |
Several state EPR laws exempt packaging for drugs and medical devices; exemptions not checked per state. |
| CanadaTrillium Therapeutics ULC and other Canadian subsidiaries3 | |
| IndiaPfizer Healthcare India Private Limited3 |
Pharmaceutical exemptions from recycled-content and reuse obligations not checked. |
| ChinaPfizer (Beijing) Research and Development Co., Ltd and others3 | GB 23350-2021 covers food and cosmetics, not medicines. |
| JapanPfizer Japan Inc.3 | |
| AustraliaHospira Adelaide Pty Ltd3 | Proposed national EPR scheme. |
| New ZealandPfizer New Zealand Limited3 | Tracker rules are single-use plastic item phase-outs; no direct match found. |
| VietnamPFIZER (VIETNAM) LIMITED COMPANY3 | |
| PhilippinesHospira Philippines, Inc.3 | |
| IndonesiaPT. Pfizer Indonesia3 | |
| ChilePfizer Chile S.A.3 | |
| ColombiaPfizer S.A.S.3 | |
| BrazilPfizer Brasil Ltda.3 | |
| KenyaPfizer Laboratories Limited3 | |
| South AfricaPfizer Laboratories (Pty) Limited3 | |
| United Arab EmiratesPfizer Gulf FZ-LLC3 | Dubai rule targets single-use plates, cutlery, cups and lids; no direct match. |
Plastic taxes: Plastic taxes in the tracker: UK Plastic Packaging Tax (PR-GB-001), where immediate packaging of licensed human medicines is exempt but secondary and transport plastic is not, and Spain's non-reusable plastic packaging tax (PR-ES-001), where medicinal exemptions were not checked. The EU plastic own resource (PR-EU-017) is paid by Member States, not by companies.
Hospira UK Limited and other UK subsidiaries are listed in Exhibit 213. Immediate packaging of licensed human medicines is outside PR-GB-001, but plastic secondary and transport packaging such as shipper liners is taxable when it holds under 30% recycled plastic. PR-GB-002 and PR-GB-003 set EPR reporting and modulated fees on packaging placed on the UK market.
PR-GB-001 UK Plastic Packaging TaxPR-GB-002 UK packaging EPR regulations (pEPR) 2024PR-GB-003 PackUK year 2 (2026-27) modulated packaging EPR feesPfizer is headquartered in New York, with U.S. revenues of USD 37,078 million in 20252. Cartons, shippers and pallets in Oregon, Colorado, California and Washington come under PR-US-002, PR-US-003, PR-US-004 and PR-US-008 unless a state drug or medical device exemption applies. The 3R work on tertiary materials bears most directly on these laws.
PR-US-002 Oregon Plastic Pollution and Recycling Modernization Act (SB 582)PR-US-003 Colorado Producer Responsibility Program for Statewide Recycling (HB22-1355)PR-US-004 California SB 54 packaging EPR and permanent regulationsPR-US-008 Washington Recycling Reform Act (SB 5284)Subsidiaries across the EU include Pfizer Deutschland GmbH and Pfizer, S.L.U.3. The PPWR (PR-EU-001) reaches secondary cartons and transport packaging, and PR-EU-009 caps empty space in transport packaging at 50% from 2030, which matters for cold chain shippers. Medicinal immediate packaging has exemptions from some PPWR design and recycled-content rules.
PR-EU-001 EU Packaging and Packaging Waste Regulation (PPWR) appliesPR-EU-009 PPWR: maximum 50% empty space in grouped, transport and e-commerce packagingPfizer Deutschland GmbH is listed3. PR-DE-001, the VerpackDG in force from 12 August 2026, requires producers selling packaged goods in Germany to register in the LUCID packaging register and finance recycling through system participation, which covers the sales packaging around medicines.
Pfizer Healthcare India Private Limited is listed3. PR-IN-001 requires brand owners and importers of plastic-packaged goods to register on CPCB's portal and meet EPR targets; how PR-IN-002 and PR-IN-003 treat pharmaceutical packaging was not checked.
PR-IN-001 EPR Guidelines for plastic packaging (PWM Rules Schedule II)PR-IN-002 Recycled content in plastic packaging (PWM Rules Schedule II, revised 2026)PR-IN-003 Reuse targets for rigid plastic packaging (PWM Rules Schedule II, revised 2026)SPI analysis Our reading of the sourced facts above. Not company-reported, not legal advice.
Pfizer publishes no numeric packaging targets, so its packaging demand signals come from qualitative aims and from its climate programme. The clearest signal is in transport and cold chain packaging: the 2025 Impact Report says Pfizer is prioritising reduction, reuse and recycling of high-volume tertiary shipment materials and piloting reusable thermal blankets and lighter wooden pallets. Its packaging page also asks for lower-carbon materials, fewer chemicals of concern, more recycled content and take-back programs run with suppliers. Because 72% of suppliers by spend already have science-based climate targets and Pfizer aims for a 90% cut in value chain emissions by 2040, packaging suppliers should expect to be asked for emissions data and reduction plans. Primary packaging for medicines is tightly regulated and changes slowly, but secondary cartons, shippers and pallets in the EU, UK, U.S. EPR states and India sit inside packaging laws that partly exempt medicines. No supplier relationship has been publicly announced, so this describes demand signals, not who supplies.
No numeric packaging target or target year appears on Pfizer's packaging page or in its 2025 Impact Report, published on 2 June 202654. Its aims are to cut packaging on existing products, optimise packaging for new launches, use lower-carbon and recycled materials, and run take-back programmes with suppliers.
No. The goal that 64% of purchased goods and services suppliers by spend set science-based greenhouse gas targets by 2025 is a supplier-climate target8. Pfizer reported 72% in 2025, but the measure says nothing about packaging materials, weight or recyclability.
The 2025 Impact Report focuses on high-volume tertiary shipment materials under the 3R Circular Program4. Pfizer is piloting reuse of cold chain thermal blankets and lighter-weight wooden pallets. No quantities had been published as of October 2026.
Pfizer's package designers use an internal life cycle assessment tool to estimate the environmental impact of designs5. It supports the aim of choosing materials with lower greenhouse gas profiles, but no results from it were published in the sources read on 14 October 2026.
Pfizer aims to cut value chain emissions 90% from 2019 by 20406. Purchased goods include packaging, so packaging suppliers fall inside that Scope 3 goal. Pfizer paused SBTi validation of the net-zero target in 2024.
What the sources reviewed do not show, or what we could not confirm. Know something we have missed? Tell the SPI team and we will check it.
SPI analysis sections written by the SPI team on 14 October 2026. Not company-reported, not legal advice.
Targets in the register above link to their own source. Facts are summarised in the SPI team's words; quotes are marked.
Selling packaging to these companies?
We map a buyer's public commitments and deadlines to the materials and formats they affect, and assess the opportunity for converters and material suppliers.
Prefer email? Write to sales@strategicpackaginginsights.com.
We compare the realistic alternatives on recyclability evidence, regulatory fit and cost direction, and say where the evidence is thin.
We benchmark the public packaging commitments and reported progress of the companies you name, each with its source.